An official government website affiliated with the Government of the Kingdom of Saudi Arabia
In a new research achievement, Dr. Salem bin Salman Al-Majri, a faculty member at the Department of Pharmacology, College of Pharmacy 
at King Khalid University, has been granted a patent for his innovation, “Modified Subunit Vaccine for Tuberculosis.”
The invention, officially registered with the Saudi Authority for Intellectual Property , involves the development of an innovative DNA vaccine for the prevention of tuberculosis. It is based on a modified genetic antigen derived from Mycobacterium tuberculosis. The gene was modified using genetic engineering techniques to enhance antigen production within mammalian cells and stimulate the immune response.
Highlighting the invention’s key features, Dr. Al-Majri explained that the modifications contributed to the development of a unique genetic sequence with properties suitable for use as a DNA vaccine. The final product is also stable at room temperature, reducing the need for refrigeration and specialized transportation compared with certain temperature-sensitive vaccines. Additional advantages include lower production costs and the potential for large-scale manufacturing.
He noted that tests conducted on an animal model (mice) demonstrated a notable protective capacity of the modified vaccine compared with non-immunized groups, along with a strong immune response, supporting the potential for further development and investigation of its future applications.
The significance of the invention lies in its focus on tuberculosis, one of the world’s most widespread infectious diseases according to the World Health Organization . Given the variable effectiveness of the currently approved BCG vaccine in protecting adults and the risks it may pose to immunocompromised individuals because it contains live bacteria, this invention offers a bacteria-free genetic vaccine, providing a potentially safe preventive option that could represent a valuable addition to existing approaches for preventing the disease.
Regarding the vaccine’s future applications, Dr. Al-Majri explained that it could be further developed for use as a booster to the BCG vaccine or as a standalone option for certain individuals for whom live vaccines are unsuitable, following completion of the necessary development stages and studies to establish its safety and efficacy in humans.
This achievement extends King Khalid University’s efforts to advance scientific research and innovation and support its faculty and staff in transforming research outcomes into innovations with tangible impact, contributing to strengthening the University’s role in addressing health challenges and supporting society.
